rationale for combination therapy in mrcc
Published 6 years ago • 80 plays • Length 5:12Download video MP4
Download video MP3
Similar videos
-
3:43
the rationale behind combination therapy in mrcc
-
1:25
dr. sznol on patient selection for combination therapy in mrcc
-
3:15
tki/i-o therapy in mrcc
-
1:47
dr agarwal on the rationale for novel combination therapies in mcrpc
-
1:34
dr. powles on rationale for keynote-426 in mrcc
-
9:05
mrcc: when is tki/i-o combination therapy appropriate?
-
4:18
mrcc: how an approved i-o regimen impacts treatment
-
3:42
second-line combination therapy in mrcc
-
1:19
dr. alva on the shift toward combination therapy in mrcc
-
7:54
combination therapies in renal cell carcinoma
-
4:42
making decisions for second-line therapy in mrcc
-
2:18
dr. joseph on selecting frontline therapy in mrcc
-
7:49
immunotherapeutic combinations for mrcc: immotion-151
-
11:30
immune checkpoint inhibitors in combination therapy for rcc
-
10:15
novel combinations in mrcc: axi/pembro vs axi/avelumab
-
2:00
nivolumab and ipilimumab in mrcc
-
10:38
considerations for using adjuvant therapy in mrcc
-
8:07
vegf tki immunotherapy combinations for mrcc
-
3:42
lenvatinib and everolimus in relapsed/refractory mrcc